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ABSTRACT
Objective. C-reactive protein (CRP) and homocysteine are markers of cardiovascular risk that may have inﬂamma-
tory effects. HMG coenzyme A reductase inhibitors (statins) have anti-inﬂammatory effects in vitro, but it is not clear
if such responses in vivo are secondary to lipid lowering. We examined the hypothesis that CRP and homocysteine
would stimulate cytokine release in human whole blood and that short-term treatment with a statin would inhibit it.
Methods. The time course of IL-6 and MCP-1 production was determined in whole blood incubated with saline,
1 mg/mL lipopolysaccaride (LPS), 50 and 100 mM/L DL-homocysteine, and 5 mg/mL human recombinant CRP for
24 hours at 37°C under 5% CO2 atmosphere. Cytokine responses were determined in blood drawn from 15 healthy
volunteers before and after administration of pravastatin 40 mg daily for 2 days.
Results. Both human recombinant CRP and LPS signiﬁcantly increased the production of IL-6 and MCP-1 in
whole blood samples more than 4-fold (P < 0.001) but homocysteine did not. Oral administration of pravastatin,
40mg daily for 2 days, decreased CRP-stimulated IL-6 production by approximately 20% (P = 0.02) 6 hours after
incubation, but did not affect MCP-1 production (P = 0.69). Pravastatin treatment did not affect LPS-stimulated
MCP-1 but increased IL-6 modestly.
Conclusions. CRP stimulated the production of the proatherogenic mediators MCP-1 and IL-6 in human whole
blood, but homocysteine did not. CRP-stimulated production of IL-6, but not MCP-1, was modestly attenuated by
short-term treatment with pravastatin.
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M
any studies have shown that C-reactive
protein (CRP) and homocysteine concen-
trations are associated with increased cardiovascu-
lar risk [1,2]. Elevated concentrations of CRP are
associated with increased risk of coronary events
and mortality in patients with coronary artery
disease, other high-risk individuals, and apparently
healthy people, independent of other cardiovascu-
lar risk factors [3,4]. Similarly, increased homocys-
teine concentrations are an important risk factor
for coronary heart disease in both healthy subjects
[5] and patients with ischemic heart disease [6]. It
is not clear to what extent homocysteine and CRP
may contribute directly to coronary risk, but
recent in vitro studies indicate that they may have
pro-atherogenic effects.
Homocysteine induced the expression and
secretion of the pro-atherogenic chemokine,
monocyte chemoattractant protein-1 (MCP-1),
and the cytokine, interleukin-8 (IL-8), in human
aortic endothelial cells [7]. Similarly, although
CRP has traditionally been considered to be a non-
speciﬁc acute phase reactant, it induced monocyte
activation and adhesion, and the expression and
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human endothelial cells [8]. Thus, homocysteine
and CRP appear to act not only as markers of
cardiovascular risk, but based on in vitro studies, to
induce inﬂammatory responses and thus perhaps
play a direct role in the pathogenesis of atheroscle-
rosis. However, whether these pro-inﬂammatory
effects of CRP and homocysteine occur in vivo is
not clear.
Drugs that inhibit hydroxymethyl glutaryl
(HMG) coenzyme A reductase activity (statins)
decrease the production of low-density lipoprotein
(LDL) cholesterol and up-regulate the expression
of LDL-receptors [9]. Statins reduce cardiovascu-
lar mortality, but appear to do so to a greater
extent than would be predicted from the LDL
cholesterol reduction achieved [10]. Accordingly,
other mechanisms have been sought through
which statins may decrease cardiovascular risk.
Anti-oxidant, antiproliferative, immunomodula-
tory and anti-inﬂammatory effects have been iden-
tiﬁed in vitro and as a result the effects of statins
have been described as pleiotropic [11]. However,
little is known about the in vivo anti-inﬂammatory
effects of statins and whether these are indepen-
dent of cholesterol lowering.
Treatment with statins consistently decreases
plasma CRP concentrations [12,13]. Statins also
reduce the serum levels and the expression of
proinﬂammatory cytokines and chemokines in
leukocytes from treated hypercholesterolemic
patients [14]. However, the effects of statins on
CRP and cytokines in vivo have been studied
after several weeks of treatment when effects on
cholesterol have already occurred, and thus
anti-inﬂammatory effects may be secondary to
lower cholesterol concentrations. We postulated
that if statins have a direct anti-inﬂammatory
effect in vivo this effect would occur rapidly, as it
does in vitro.
First, we examined the hypothesis that CRP and
homocysteine would stimulate the production of
IL-6 and MCP-1, proatherogenic cytokines, in
whole blood and second, that this effect would be
attenuated by short-term treatment with a statin.
Methods
The study was approved by the Institutional
Review Board of Vanderbilt University Hospital
and all subjects gave written informed consent.
We studied 15 healthy subjects (6 male and 9
female; 6 Caucasian, 5 African American, 3 Asian
and 1 Hispanic) who had not taken any medica-
tions for at least 7 days and no alcohol or caffeine
for at least 2 days before the study. The subjects
had an average (SEM) age of 27  1 years and
weight of 73.1  3.6 kg. Subjects were fasted over-
night and venous blood (50 mL) was drawn. Sub-
jects then swallowed pravastatin 40 mg with water
in the presence of an investigator. Twenty four
hours later subjects received a second 40 mg dose,
again in the presence of an investigator, and 1.5
hours later, a time when peak concentrations of
pravastatin are expected to occur, 50 mL blood
was drawn. Several studies have shown that the
mean time to reach maximum concentration of
pravastatin is approximately 1.5 hours (range,
0.5–4 hours) [15], thus we drew blood for the
ex vivo studies 1.5 hours after administration of
pravastatin.
Venous blood from these volunteers was col-
lected into tubes containing heparin, maintained at
37°C, and studied within 60 minutes. Cytokine
production ex vivo was measured as previously
described by ourselves and others [16,17]. Eight
hundred ml of heparinized whole blood was incu-
bated with 200 mL saline (control), lipopolysaccar-
ide (LPS, Escherichia coli O111:B4 from Sigma,
St. Louis, MO) (ﬁnal concentration 1 mg/mL,
n = 15), human recombinant CRP (Calbiochem,
San Diego, CA) (ﬁnal concentration 5 mg/mL,
n = 15) or DL-homocysteine (Sigma, St Louis,
MO) (ﬁnal concentration 50 mM/L, n = 8, and
100 mM/L, n = 6) for 24 hours at 37°C under 5%
CO2 atmosphere. At 0, 6, 10 and 24 hours samples
were centrifuged in an Eppendorf microcentrifuge
at 1,500 ¥ g for 10 minutes. Supernatants were
stored at –70°C until IL-6 and MCP-1 concentra-
tions were measured. The 6-hour time-point was
of primary interest as regards the effects of prav-
astatin because this was the shortest incubation
period that we had shown in pilot studies resulted
in a robust stimulation of cytokines by CRP. The
experiments to determine the effects of homocys-
teine on cytokine production were discontinued
when it was became clear after studying 7 subjects
that there was no effect.
Measurement of Cytokine and
Pravastatin Concentrations
IL-6 and MCP-1 concentrations were measured
using enzyme linked immunosorbent assay kits
(R&D systems, Minneapolis, MN). All samples
were analyzed in duplicate and results averaged.
In order to correct for spontaneous cytokine
generation, the net production of cytokines was
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saline controls from those induced by LPS or CRP.
Pravastatin concentrations were measured by
HPLC. A 100 mg C18 preparatory solid-phase
extraction column (Sep-Pak Vac, Waters, Missis-
sauga, ON) was initially washed with 1ml volumes
of isopropyl alcohol, methanol and water. An
aliquot (1,000 mL) of plasma was added and the
column was washed three times with 1ml of acetic
acid: methanol: water (2:10:88 v/v) and then three
times with 1 mL ammonium hydroxide: methanol:
water (2:10:88 v/v). The sample was eluted with
1ml methanol containing triethylamine (200 mL/
100 mL) and it was evaporated to dryness at 40°C
under a gentle stream of nitrogen. The residue was
dissolved in an aliquot (100 mL) of HPLC mobile
phase which consisted of acetonitrile: water (27:73
v/v) and triethylamine 500 mL/L at pH = 3.0 with
phosphoric acid that also contained the internal
standard, 5-methoxypsoralen, (Indoﬁne Chemical
Company Inc., Somerville, NJ) at a concentration
of 500 ng/mL. The solution was ﬁltered (0.45 mM)
and a sample (30 mL) was injected onto a
150 mm ¥ 3.2 mm Prodigy C18, 5 mm column
(Phenomenex, Torrance, CA) at a mobile ﬂow rate
of 0.4 mL/min. Absorbance detection at 238 nm
was used to monitor the efﬂuent. The retention
times of pravastatin and 5-methoxypsoralen were
13 and 23 minutes, respectively. The standard
curve of pravastatin was linear over the range
tested (0–200 ng/mL). The coefﬁcient of variation
was 3.3% at 25 ng/mL (n = 7) and the limit of
detection was 5 ng/mL.
Measurement of Endotoxin Concentration
Recombinant human CRP contains low concen-
trations of endotoxin which were measured using a
limulus amebocyte lysate assay (Cape Cod, Fal-
mouth, MA) which has a lower limit of detection
of 0.005 Endotoxin Units (EU).
Statistical Analysis
Results are expressed as mean  SEM in the text
and ﬁgures. Wilcoxon signed ranks tests were used
to compare cytokine production in stimulated and
in unstimulated whole blood and to compare
stimulated IL-6 and MCP-1 production before
and after the administration of pravastatin. Corre-
lations were assessed by Spearman’s rank order
test. Values of P < 0.05 were considered signiﬁ-
cant. Statistical analysis was performed with SPSS
11.5 for Windows (SPSS, Chicago, IL).
Results
Effects of CRP and DL-homocysteine on IL-6 and
MCP-1 Production
The major ﬁndings of this study are that human
recombinant CRP, but not homocysteine, stimu-
lates cytokine production in human whole blood
and that short-term treatment with a statin
modestly inhibits CRP-stimulated IL-6 but not
MCP-1 production after 6 hours of incubation.
LPS and recombinant CRP increased IL-6
(Figure 1a) and MCP-1 (Figure 1b) production
signiﬁcantly (all P values < 0.001 compared
to saline control). This effect occurred rapidly,
within 6 hours. Neither 50 nor 100 mM/L
DL-homocysteine affected MCP-1 or IL-6 pro-
duction signiﬁcantly compared to saline (all P
values > 0.07) (Figure 1a, b). Pravastatin reduced
CRP-stimulated IL-6 production from 36.6 
4.3 ng/mL (median 34.1) to 27.4  3.3 ng/mL
(median 25.5), an average of –19.7%  8.3%
after 6 hours of incubation (P = 0.02, Figure 2)
but not after longer periods of incubation
(Table 1). Pravastatin did not inhibit IL-6
production after 6 hours of incubation with
LPS (55.1  2.9 ng/mL compared to 51.4 
3.4 ng/mL before pravastatin, P = 0.09). IL-6
concentrations in LPS-stimulated whole blood
for 10 hours tended to increase after subjects
took pravastatin (P = 0.04, Table 1). Pravastatin
did not affect CRP or LPS stimulated MCP-1
cytokine production (Table 2).
Plasma Pravastatin Concentrations
The mean plasma pravastatin concentration was
50.3  9.7 ng/mL (range 5–159.6 ng/mL). There
was no signiﬁcant correlation between plasma
pravastatin concentrations and percent change
in CRP-stimulated IL-6 (r = –0.31, P = 0.27)
or MCP-1 concentrations (r = 0.16, P = 0.56),
or LPS-stimulated IL-6 (r = –0.49, P = 0.07)
and MCP-1 concentrations (r = –0.15, P = 0.27).
There was a weak negative correlation
between pravastatin concentration and absolute
reduction in IL-6 concentration (r = –2.329,
P = 0.02).
Endotoxin Concentration
The average concentration of endotoxin in
5 mg/mL recombinant CRP (n = 4) was 0.38 
0.21 EU/mL and was >8 EU/mL in LPS 1 mg/
mL, 100 ng/mL and 10 ng/mL, and 1.36 EU/mL
in 1 ng/mL (n = 2, each).
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We found that human recombinant CRP stimu-
lated production of the inﬂammatory cytokines
IL-6 and MCP-1 in whole blood but that
homocysteine did not. Short-term treatment with
an HMG co-enzyme A reductase inhibitor, prav-
astatin, reduced IL-6 production modestly after
stimulation by CRP and tended to increase IL-6
production after LPS.
Increasing evidence implicates CRP as a con-
tributor to the pathogenesis of atherosclerosis.
CRP accumulates in the macrophage rich areas of
the atherosclerotic plaque [18] and increases the
expression and release of macrophage derived pro-
inﬂammatory cytokines such as interleukin-1b and
IL-6 [19,20]. In endothelial cells, CRP increased
the expression of vascular cell adhesion molecule
(VCAM-1) and intracellular adhesion molecule
(ICAM-1), and increased MCP-1 production and
tissue factor release [8,21]. Based on in vitro and
in vivo data we selected the concentration of CRP
for study, 5 mg/mL. Thus, in patients with stable
Figure 1 (a) Time course of IL-6
production in whole blood. (b)
Time course of MCP-1 production in
whole blood. LPS and recombinant
CRP induced IL-6 and MCP-1
release in whole blood culture. Data
are expressed as mean  SEM.
*P < 0.001 compared with control
(IL-6 and MCP-1 production in
unstimulated whole blood).
a
b
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>3 mg/mL are associated with an increased risk of
coronary events [22,23] and in vitro concentra-
tions of 5 mg/mL had signiﬁcant inﬂammatory
effects [24].
We found that recombinant CRP markedly
increased the production of IL-6 and MCP-1,
cytokines that are thought to be important in the
pathogenesis of atherosclerosis [25,26]. Human
recombinant CRP is known to contain low con-
centrations of endotoxin. The question arises
whether this could account for the ability of CRP
to stimulate cytokine production. Various strate-
gies, such as boiling CRP to destroy it and thus
isolate the contribution of endotoxin to observed
responses, or passing CRP through columns con-
taining polymyxin to remove endotoxin, have been
explored. However, low levels of endotoxin are
present in apparently healthy subjects [27,28] and
have been associated with risk of atherosclerosis
[28]. Much higher levels of endotoxin (>50 pg/
mL) are observed in subjects with chronic or
recurrent bacterial infections, another risk factor
for atherosclerosis [29]. Thus, considering the
possibility that CRP and endotoxin are both risk
factors for atherosclerosis and may act synergisti-
cally in vitro [20] and in vivo, our strategy was not
to remove the endotoxin present in CRP but to
measure the concentrations present. The concen-
trations of endotoxin present in CRP were low,
generally less than 0.5 EU/mL, are unlikely to
account for the cytokine stimulation by CRP [30].
Thus our studies suggest that human recombinant
CRP in the presence of very low levels of endot-
oxin stimulates IL-6 and MCP-1 production in
whole blood.
Treatment with a statin for several weeks has
been shown to decrease CRP production [12] and
to reduce the expression of IL-6, IL-8, and
MCP-1 mRNA in peripheral blood cells and to
decrease serum cytokine concentrations [31,32].
Statins have rapid anti-inﬂammatory effects in
vitro decreasing the production of cytokines within
hours [8,33,34]. Studies that have examined the
Figure 2 Effect of pravastatin on IL-6 production in whole
blood during stimulation with 5 g/mL recombinant CRP for
6 hours (n = 15). Administration of pravastatin reduced
CRP-stimulated IL-6 production by an average of –20%
(P = 0.02).
Table 1 IL-6 production in recombinant CRP or LPS-stimulated whole blood before and after administration of pravastatin
Incubation time
IL-6 concentration (ng/ml)
P values Before pravastatin After pravastatin
Unstimulated (Saline)
6 hours 0.09  0.05 0.10  0.05 0.83
10 hours 0.09  0.05 0.13  0.06 0.50
24 hours 0.13  0.06 0.16  0.06 0.78
5 mg/ml CRP
6 hours 35.2  17.5 25.5  13.6 0.02
10 hours 39.3  3.27 33.6  3.90 0.14
24 hours 42.3  3.28 40.6  4.26 0.61
1 mg/ml LPS
6 hours 51.4  3.4 55.1  2.9 0.09
10 hours 61.5  4.69 69.9  4.08 0.04
24 hours 75.9  20.1 80.7  18.8 0.36
Values are mean SEM from 15 experiments performed in duplicates.
The net production of IL-6 was calculated by subtracting the concentration without stimulus from those induced by LPS or recombinant CRP.
Wilcoxon signed rank test was applied for statistical analysis.
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have done so after several weeks of treatment [12]
and thus have not separated out direct antiinﬂam-
matory effects from those due to the reduction
in lipids and CRP [31]. Treatment with a statin
decreases CRP and LDL cholesterol concentra-
tions rapidly, with effects seen after 14 days [35].
However, treatment for 3 to 6 days does not alter
LDL cholesterol concentrations [36] indicating
that the effects noted in the present study after two
doses are not likely to be secondary to lowering of
cholesterol.
We chose to study pravastatin; there were
several rationales for this choice. First, it is widely
used clinically, and since it is not a CYP3A4 sub-
strate has fewer interactions with other drugs.
Second, an anti-inﬂammatory effect of pravastatin
has been well demonstrated. Randomized, double-
blind studies have shown that several statins
decrease concentrations of C-reactive protein
(CRP) and that the reductions obtained with dif-
ferent statins were similar [12]. However, the
effect of pravastatin on CRP was independent of
its lipid-lowering effects [13].
The ﬁnding that treatment with a statin has a
rapid inhibitory effect on CRP stimulated IL-6
production is of interest, not only because it dem-
onstrates a rapid anti-inﬂammatory action of a
statin ex vivo, but also because IL-6 is thought to
be one of the prime regulators of CRP production
[37]. Furthermore, our ﬁndings suggest that CRP
may stimulate IL-6. Concordant with this notion
is the observation that CRP and IL-6 concentra-
tions are correlated [38,39]. Thus the inhibitory
effect of statins on CRP could be mediated in part
by effects on IL-6.
The effects of pravastatin on CRP stimulated
IL-6 production varied among individuals. Since
pravastatin concentrations are known to vary more
than 10-fold among individuals receiving the same
dose [40], we examined the possible relationship
between pravastatin concentrations and the
change in cytokine production. There was no cor-
relation between pravastatin concentrations and
effect suggesting that variability in drug concen-
trations does not contribute substantially to the
differences observed among individuals.
An inhibitory effect of pravastatin was observed
on CRP-stimulated IL-6 after 6-hour incubation
but not after longer incubation times. It is likely
that multiple pathways of IL-6 activation are sec-
ondarily activated by the CRP-stimulated inﬂam-
mation and that these may not be sensitive to
pravastatin. Pravastatin did not affect either
MCP-1 production and tended to increase LPS-
stimulated IL-6 responses. The explanation for
this is not clear but it suggests that the anti-
inﬂammatory effects of statins may be speciﬁc to
particular cytokines and stimuli.
The lack of effect of homocysteine on cytokine
production was unexpected. Several lines of evi-
dence suggest that hyperhomocysteinemia may
be more than a marker of cardiovascular risk.
Homocysteine is rapidly auto-oxidized resulting in
the production of potent reactive oxygen species
that result in damage to endothelial cells [41].
Homocysteine also limits the bioavailability of
nitric oxide, and in cultured human aortic endot-
helial cells and THP-1 monocytes, decreases
the expression and secretion of MCP-1 [7,38].
However, the effects of homocysteine on isolated
cells in culture may not be representative of a more
Table 2 MCP-1 production in recombinant CRP or LPS-stimulated whole blood before and after administration of
pravastatin
Incubation time
MCP-1 concentration (pg/ml)
P-values Before pravastatin After pravastatin
Unstimulated (Saline)
6 hours 105.2  20.9 111.4  21.3 0.53
10 hours 157.1  35.0 150.6  31.2 0.65
24 hours 303.6  108.1 407.4  450.2 0.43
5 mg/mL CRP
6 hours 442.3  85.6 417.4  72.7 0.69
10 hours 1,291.0  229.4 1,458.9  227.6 0.31
24 hours 3,157.5  632.3 3,083.0  629.1 0.65
1 mg/mL LPS
6 hours 530.3  101.6 502.4  97.0 0.87
10 hours 759.0  441.6 750.7  471.1 0.73
24 hours 1,139.0  879.4 899.4  884.1 0.10
Values are mean SEM from 15 experiments performed in duplicates.
The net production of MCP-1 was calculated by subtracting the concentration without stimulus from those induced by LPS or recombinant CRP.
Wilcoxon signed rank test was applied for statistical analysis.
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whole blood cytokine stimulation technique is that
it provides a composite measure of response that
can involve several different cell types activated in
a biologically relevant environment.
Using concentrations of homocysteine that had
inﬂammatory effects in vitro, and are in the range
that may occur in patients with hyperhomocys-
teinemia [41], we found no effect on IL-6 or
MCP-1 production in whole blood over 24 hours
of incubation. This contrasts with responses in
human aortic endothelial cells where responses to
homocysteine occurred rapidly, plateauing within
2–8 hours, and were inhibited by cycloheximide
indicating that de novo protein synthesis had
occurred [7]. A possible explanation for the differ-
ent ﬁndings may be that the whole blood environ-
ment provides antioxidant defenses that are not
present in cell culture and may thus attenuate the
pro-inﬂammatory effects of homocysteine that are
thought to be mediated by free radicals [42]. Thus,
our ﬁndings suggest that the previous observations
that homocysteine stimulated the production of
cytokines in isolated cells in vitro may not be
generalizable to the in vivo situation.
A limitation of this study is that we did not
investigate the effect of escalating doses of pravas-
tatin. Several randomized trials have shown that
pravastatin 40 mg daily reduced CRP concentra-
tions signiﬁcantly [12,13,43], but there is no dose-
response information for this response. Therefore,
we chose a dose of pravastatin 40 mg daily as most
likely to show an effect. Future studies could
deﬁne the dose-response more completely.
In summary, human recombinant CRP with low
concentrations of endotoxin stimulated the pro-
duction of the proatherogenic mediators MCP-1
and IL-6 in human whole blood, but homocysteine
did not. CRP-stimulated production of IL-6, but
not MCP-1, was modestly attenuated by short-
term treatment with pravastatin indicating that
treatment with a statin may have rapidly anti-
inﬂammatory actions in vivo and that these effects
may be speciﬁc to particular cytokines and stimuli.
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